Article Text

Download PDFPDF

1505 Spatial profiling of the SCLC tumor microenvironment defined by high MHC-I expression reveals association with functionally relevant antigen presentation
  1. Miljenka Vuko1,
  2. Felix Segerer1,
  3. Mingchao Xie2,
  4. Monica Azqueta Gavaldon1,
  5. Andreas Spitzmüller1,
  6. Harald Hessel1,
  7. Alma Andoni1,
  8. Marco Testori1,
  9. Michael Surace3,
  10. Mari Heininen-Brown1,
  11. Jaime Rodriguez Canales3,
  12. Shashank Saran4,
  13. Helen Angell4,
  14. Guenter Schmidt5,
  15. Nicolas Brieu1,
  16. Hadassah Sade1,
  17. J Carl Barrett2,
  18. Markus Schick1 and
  19. Giulia Fabbri2
  1. 1AstraZeneca, Munich, Bavaria, Germany
  2. 2AstraZeneca, Waltham, MA, USA
  3. 3AstraZeneca, Gaithersburg, MD, USA
  4. 4AstraZeneca, Cambridge, UK
  5. 5AstraZeneca Computational Pathology GmbH, Munich, Bavaria, Germany


Background Small cell lung cancer (SCLC) is an aggressive and largely immune-cold cancer type, for which chemotherapy combined with Immuno-oncology (IO) therapies is providing benefit only in a subgroup of patients. SCLC is a highly heterogeneous cancer with at least four major subtypes.1 Among them, the ‘inflamed’ subtype is characterized by an inflamed immune gene signature and high expression of MHC class I (MHC-I) antigen presentation and shows the greatest benefit from the addition of IO treatment to chemotherapy,2 suggesting that MHC-I could serve as a biomarker for IO therapies. Here, we aimed to assess the spatial characteristics of immune cells in MHC-I high SCLC cases to investigate and support its role as a potential biomarker for IO therapies.

Methods We combined a computational pathology approach with multiplex immunofluorescence (mIF) to profile the SCLC tumor microenvironment (TME). To this end, 126 SCLC formalin-fixed, paraffin-embedded tissue samples were stained with two mIF panels consisting of six markers each: (A) PanCK, CD8, CD68, PD-1, PD-L1, and Ki67; (B) CD20, NKp46, CD1c, CD66b, ICOS, and FOXP3. Based on these panels, we investigated the location and phenotype of each cell in the tumor center and within the stroma and tumor parenchyma. Additional slides from the same tissue blocks were immunohistochemically stained with MHC-I and scored by pathologists. Starting from the observation that high MHC-I expression was associated with higher densities of CD8+ T-cells,3 we further explored the TME characteristics of MHC-I SCLC cases.

Results Beyond higher densities of CD8+ cytotoxic T-cells, we observed higher densities of FOXP3+ regulatory T-cells, and ICOS+ T-cells in the tumor center of MHC-I high cases. Considering the role of MHC-I in antigen presentation and T-cell activation, we investigated the proportion of CD8;PD-1;Ki67+ T-cells out of all CD8+ cells. Of note, we observed a compelling association of a high proportion of CD8;PD-1;Ki67+ T-cells with high MHC-I. This effect was particularly prominent in the tumor parenchyma and absent in the stroma, revealing an association with functionally relevant presentation of tumor antigens by MHC-I on SCLC tumor cells. Interestingly, we did not observe alterations in other immune cell populations like myeloid dendritic cells, macrophages, and granulocytes.

Conclusions We utilized computational pathology to comprehensively profile the composition and spatial arrangement of the TME in inflamed SCLC cases defined by high MHC-I expression. Our findings provide the functional rationale for MHC-I as a biomarker for a potentially increased response to IO therapies.4


  1. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 Mar 8;39(3):346–360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21. PMID: 33482121; PMCID: PMC8143037.

  2. Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug;11(8):1952–1969. doi: 10.1158/2159–8290.CD-20–0913. Epub 2021 Mar 11. PMID: 33707236; PMCID: PMC8338750.

  3. Vuko M, Xie M, Gavaldon MA, Segerer F, Spitzmueller A, Hessel H, Testori M, Zimmermann J, Surace M, Heininen-Brown M, Canales JR, Saran S, Angell H, Schmidt G, Sade H, Barrett C, Schick M, Fabbri G. 155 MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells. Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0155

  4. Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A. Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation. J Thorac Oncol. 2023 May 18:S1556–0864(23)00554–3. doi: 10.1016/j.jtho.2023.05.008. Epub ahead of print. PMID: 37210008.

Ethics Approval All samples from which data in this report were generated, were obtained from an internal repository. All protocols, amendments, and participant informed consent documents were approved by the appropriate institutional review boards.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.